Dr. Duc Tran, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Georgetown University School of Medicine (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 664
Licensed in Texas since 1998, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: Georgetown University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
TX license K5416 (first issued 1998; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baylor University Medical Center Dallas, TX
- Texas Health Presbyterian Hospital Dallas Dallas, TX
- Medical City Dallas Hospital Dallas, TX
- Texas Health Presbyterian Hospital Rockwall Rockwall, TX
Medical groups
- Legacy Healthcare Services Inc (3,223 clinicians)
- Texas Health Physicians Group (1,365 clinicians)
- Neurology Consultants of Dallas, P.a. (19 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 664
- Services billed
- 4,895
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 565 | 385 |
| Injection, gadoterate meglumine, 0.1 ml | 519 | 29 |
| Therapy procedure to re-educate brain-to-nerve-to-muscle function, each 15 minutes | 310 | 21 |
| Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes | 220 | 26 |
| Established patient office or other outpatient visit, 20-29 minutes | 190 | 164 |
| Therapy procedure using functional activities | 158 | 26 |
| Mri scan of brain without contrast | 151 | 139 |
| New patient office or other outpatient visit, 45-59 minutes | 126 | 126 |
| Established patient office or other outpatient visit, 40-54 minutes | 103 | 86 |
| Therapy procedure in a group setting | 73 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in Dallas, TX | 882 |
| Memantine Hcl Other prescribers in Dallas, TX | 690 |
| Sertraline Hcl Other prescribers in Dallas, TX | 301 |
| Memantine Hcl Er (memantine hcl) Other prescribers in Dallas, TX | 228 |
| Rivastigmine (rivastigmine tartrate) Other prescribers in Dallas, TX | 206 |
| Gabapentin Other prescribers in Dallas, TX | 157 |
| Rivastigmine Other prescribers in Dallas, TX | 82 |
| Pregabalin Other prescribers in Dallas, TX | 75 |
| Alprazolam Other prescribers in Dallas, TX | 64 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Dallas, TX | 51 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 30 companies reported 118 payments worth $45,414 in total to this clinician.
| Lilly USA, LLC | $43,350 |
|---|---|
| Eisai Inc. | $399 |
| AbbVie Inc. | $184 |
| Vanda Pharmaceuticals Inc. | $165 |
| Pfizer Inc. | $137 |
| Argenx US, Inc. | $137 |
| Novartis Pharmaceuticals Corporation | $136 |
| Grifols USA, LLC | $114 |
| Compensation for services other than consulting (speaking, faculty) | $42,625 |
|---|---|
| Food and Beverage | $2,528 |
| Travel and Lodging | $261 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Aug 28, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $6,250 |
| Lilly USA, LLC Jun 16, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC Oct 31, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC Apr 14, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC May 5, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC Aug 20, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC Aug 13, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC Dec 8, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
All 24 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Dec 8, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC Dec 8, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC Dec 8, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $1,575 |
| Lilly USA, LLC Dec 8, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $950 |
| Lilly USA, LLC Oct 31, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC Oct 31, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $950 |
| Lilly USA, LLC Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $950 |
| Lilly USA, LLC Aug 28, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $6,250 |
| Lilly USA, LLC Aug 22, 2025 | Travel and Lodging travel to INDIANAPOLIS, TX · in-kind | $131 |
| Lilly USA, LLC Aug 22, 2025 | Travel and Lodging travel to INDIANAPOLIS, TX · in-kind | $131 |
| Lilly USA, LLC Aug 20, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC Aug 20, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $950 |
| Lilly USA, LLC Aug 13, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC Aug 13, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $950 |
| Lilly USA, LLC Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $950 |
| Lilly USA, LLC Jun 16, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC Jun 16, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $950 |
| Lilly USA, LLC May 5, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC May 5, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $950 |
| Lilly USA, LLC Apr 14, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,500 |
| Lilly USA, LLC Apr 14, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $950 |
| Lilly USA, LLC Jan 22, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $1,250 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $335,253 in research payments for these studies, mostly to the institutions running them.
- A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)
Alnylam Pharmaceuticals Inc. - A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Eli Lilly and Company · Completed · NCT05463731 - A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company · Active, not recruiting · NCT04437511 - Evaluation of the lilly sp-x p-TAU217 assay by measuring changes in the intended patient management between pre-and post-p-TAU217 result: a randomized clinical utility study
Eli Lilly and Company - A Phase 2, Randomized, Double-blind, Placebo-controlled Parallel Group Study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) Over 40 Weeks Followed by an Open Label Extension (ASTRALS)
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.